The National Institute of Diabetes & Digestive & Kidney Diseases

Clinical trials of agents to preserve beta cell function in new onset type 1 diabetes will use C-peptide as an outcome measure that indicates insulin production. The C-peptide standardization program is supported to establish reliability in results and facilitate the conduct of international clinical trials.

For more information, contact Dr. Lisa Spain, DEM, Director, Immunobiology of Type 1 Diabetes Program and Autoimmune Endocrine Diseases Program.

The NKDEP Laboratory Working Group has launched the Creatinine Standardization Program to address inter-laboratory variation in creatinine assay calibration and provide more accurate estimates of GFR.
 
For more information, contact Dr. Andrew Narva, Director, National Kidney Disease Education Program; Senior Scientific Advisor.

The fundamental aim of DASP is to improve the measurements of the autoantibodies predictive of type 1 diabetes.

For more information, contact Dr. Beena Akolkar, DEM, Director, Immunopathogenesis and Genetics of Type 1 Diabetes Program.

The goal of this project is to improve HbA1c measurements and data interpretation across clinical systems and national harmonization projects.